Chemotherapy Combined With Pembrolizumab in Treating Patients With Thymoma and Thymic Carcinoma
This is an investigational, single arm study.
Thymoma and Thymic Carcinoma
DRUG: Chemotherapy+Pembrolizumab.
Objective Response Rate., Response rate assessed by the site investigators according to the Response Evaluation Criteria In Solid Tumors (RECIST v1.1)., After 4 cycles (each cycle is 21 days) treatment up to 4 years.
Progression-free Survival., Response rate assessed by the site investigators according to the Response Evaluation Criteria In Solid Tumors (RECIST v1.1)., After 4 cycles (each cycle is 21 days) treatment up to 4 years.
Pembrolizumab is FDA approved and commercially available for treatment of many types of cancers. It is considered investigational to use chemotherapy combined with pembrolizumab to treat thymoma or Thymic carcinoma.

Subjects will be evaluated for eligibility during a 28-day screening period. Eligible subjects will receive 4 cycles carbo-paclitaxel/ nab-paclitaxel combined with pembrolizumab. Response rate assessed by the site investigators according to the Response Evaluation Criteria In Solid Tumors (RECIST v1.1).

Up to 40 participants will be enrolled in this study.